DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for primary hypertrophic osteoarthropathy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrimary hypertrophic osteoarthropathy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for primary hypertrophic osteoarthropathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier organic anion transporter family member 2A1 (SLCO2A1) — SLCO2A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KGW · 2.96 Å · ligand (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid (P2E). Experimental structure, not a prediction.
What the evidence adds up to
In 2002 a 29-year-old man with primary hypertrophic osteoarthropathy had finger clubbing from age 15, disproportionate growth of hands and feet over ten years, whole-body sweating especially of the hands and feet, and persistent limb and joint pain. Biochemical and endocrinological tests were normal. Hand and lower-leg radiographs showed marked periosteal thickening with unremarkable trabecular bone. Secondary causes were excluded. There is no causal treatment; physiotherapy and balneotherapy improved symptoms in that patient. The authors state that early accurate diagnosis is essential because of the favourable long-term prognosis.
A 2020 review describes primary hypertrophic osteoarthropathy as a rare hereditary disease with autosomal dominant and autosomal recessive inheritance. Genetic heterogeneity produces clinical polymorphism of symptoms that appear in childhood and adolescence. Differential diagnosis must exclude secondary hypertrophic osteoarthropathy, which occurs in 90% of cases and is associated with malignant neoplasms, rheumatic diseases, and other conditions. X-ray signs are important for clarifying the location, extent, and nature of bone lesions. The review states there is no specific treatment.
A 1998 paper on secondary hypertrophic osteoarthropathy emphasises that when hypertrophic osteoarthropathy is diagnosed, a search for the underlying pathology is imperative. The disorder is usually associated with a primary pulmonary lesion and presents with periostitis and paresthesias of the lower extremities. Recognising the primary pathology is essential for effective treatment of the secondary form. A 2021 case report describes a lung cancer patient whose hypertrophic pulmonary osteoarthropathy was visualised on both bone scintigraphy and somatostatin receptor scintigraphy, the first such report using the latter technique.
No controlled trials of any drug for primary hypertrophic osteoarthropathy exist in these abstracts. What is missing is any trial design, any patient stratification by genetic subtype, and any funding for a specific treatment study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the American Podiatric Medical Association · 1998 · 5 citations
Secondary hypertrophic osteoarthropathy
AbstractWhenever hypertrophic osteoarthropathy is diagnosed, it is imperative to search for the underlying pathology. The disorder is usually associated with a primary pulmonary lesion and periostitis and paresthesias of the lower extremities. Recognizing and understanding the primary pathology is essential to the effective treatment of secondary hypertrophic osteoarthropathy.
AbstractHISTORY: A 29-year-old man had finger clubbing since the age of 15 years, and for the last 10 years his hands and feet had grown disproportionately. In addition he suffered from marked whole-body sweating, especially of the hands and feet, as well as persistent pain in the limbs and joints. INVESTIGATIONS: Biochemical and endocrinological tests were normal. Radiology of the hands and lower legs revealed marked periosteal thickening, while the substantia trabeculosa was unremarkable. Secondary causes having been excluded primary hypertrophic osteoarthropathy was diagnosed. TREATMENT AND COURSE: While there is no causal treatment, physio- and balneotherapy improved the symptoms. CONCLUSION: Early and accurate diagnosis of primary hypertrophic osteoarthropathy is essential, if only because of its favourable long-term prognosis.
Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and somatostatin receptor scintigraphy
AbstractHypertrophic osteoarthropathy (HOA) as a paraneoplastic disorder is most often associated with pulmonary malignancies 1 . Bone scintigraphy (BS) is known to be useful for detecting HOA 1,2 . Here, we present a lung cancer patient who demonstrated findings consistent with HOA on BS and somatostatin receptor scintigraphy (SRS). To the best of our knowledge, this is the first report of HOA visualized by SRS.
Rheumatology Science and Practice · 2020 · 0 citations · open access
Primary hypertrophic osteoarthropathy
AbstractThe article presents information about a rare hereditary disease – primary hypertrophic osteoarthropathy with autosomal dominant and autosomal recessive inheritance. Genetic heterogeneity is responsible for the clinical polymorphism of symptoms that appear in childhood and adolescence. Differential diagnosis should be carried out with secondary hypertrophic osteoarthropathy, which occurs in 90% of cases and is associated with malignant neoplasms, rheumatic diseases and other diseases. X-ray signs are of great importance to clarify the localization, extent and nature of bone lesions. There is no specific treatment for the disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
